Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension

Jeffrey S. Plotkin, Paul C. Kuo, Lewis J. Rubin, Sean Gaine, Charles D. Howell, Jacqueline Laurin, Mary J. Njoku, James W. Lim, Lynt B. Johnson

Research output: Contribution to journalArticlepeer-review

113 Scopus citations


Background. Portopulmonary hypertension, defined as mean pulmonary artery pressure >25 mmHg in the presence of a normal pulmonary capillary wedge pressure and portal hypertension, is a known complication of end-stage liver disease that has been associated with high morbidity and mortality at the time of liver transplantation. We have recently reported the successful treatment of portopulmonary hypertension with chronic intravenous epoprostenol and now report the first patient with severe portopulmonary hypertension successfully treated with epoprostenol who subsequently underwent successful liver transplantation. Methods. A patient with severe portopulmonary hypertension was treated with intravenous epoprostenol, 23 ng/kg/min, for a 4-month period, after which the portopulmonary hypertension resolved and the patient underwent successful liver transplantation. Results. The patient was discharged, continues to do well, and at 3 months is off epoprostenol with near normal pulmonary artery pressures. Conclusions. Chronic epoprostenol, in conjunction with a multidisciplinary, well-planned perioperative evaluation and treatment plan, may be the answer to a heretofore untreatable disease.

Original languageEnglish (US)
Pages (from-to)457-459
Number of pages3
Issue number4
StatePublished - Feb 27 1998
Externally publishedYes

ASJC Scopus subject areas

  • Transplantation


Dive into the research topics of 'Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension'. Together they form a unique fingerprint.

Cite this